NEW YORK—An investigational triple regimen of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) may result in significantly greater mean reductions in BP compared ...
Proportion achieving target BP increased with use of triple combo pill versus usual care at six months. TUESDAY, Aug. 14, 2018 (HealthDay News) — Treatment with a pill combining low doses of 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback